PhD , Senior Researcher Head of the Scientific Laboratory of Hemostasis Pathology Tashkent, Toshkent, Uzbekistan
Background: In a retrospective study of pre-thrombotic conditions in hematological patients who are hospitalized at the Hematology Center (Uzbekistan) for 2018-2021, it turned out that they occur in such pathologies as: chronic myeloid leukemia (250 patients), polycythemia vera (68 patients), subleukemic myelosis (49 patients), myeloma (413 patients), Waldenström's disease (30 patients), chronic megakaryocytic leukemia (23 patients), as well as vasculitis (69 patients). In total, 902 patients with these pathologies were registered for 2021, which is significantly more than in 2020 (850) and 2019 (835 patients).
Aims: The goal is to determine the readiness for thrombosis in patients undergoing polychemotherapy.
Results: For the examined group 1 (with signs of thrombosis in anamnesis), shortening of the activated partially thromboplastin time is characteristic compared to the control -33.7±2.5, (p < 0.05), and in group 2 with acute thrombosis (30 .2±1.9sec; P2< K < 0.05 and P3 < 1-2 < 0.5). The indicators of the prothrombin index (PTI) were within the normal range (p≥0.05), which made it possible to exclude a defect in phase II blood coagulation factors in all patients. As for fibrinogen, as a marker of any inflammatory reaction, a high level of fibrinogen was found in patients with acute thrombosis, relative to group 1 (P3 < 1-2 < 0.05).
Conclusion(s): The data obtained in the course of the study indicate that during chemotherapy, the activation of the blood coagulation system occurs, which can lead to acute recurrent rethrombosis, and therefore an early start of prophylaxis with anticoagulants is necessary.
